Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor
(FGFR) 1-3. This is a multicenter, open-label, single arm phase IIa study to evaluate the
efficacy and safety of Infigratinib in subjects with locally advanced or metastatic gastric
cancer or gastroesophageal junction adenocarcinoma with FGFR2 genetic amplification or other
advanced solid tumors with other FGFR genetic alternations who have failed in 2nd line or
above treatment. This trial includes up to 3 cohorts (i.e., baskets) with above mentioned
indications.